Eisai today announces that Halaven (eribulin) will remain on the National Cancer Drugs Fund (NCDF) pending reconsideration by the NCDF panel. The reconsideration is the result of the appeals submitted by Eisai following the original decision by NHS England to remove eribulin from the NCDF. Eribulin will remain available to patients pending the result of the reconsideration.

Eribulin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.

Eribulin remains the only single agent chemotherapy to significantly improve overall survival in women with advanced breast cancer after anthracycline and taxane treatment. To date, eribulin is the sixth most prescribed treatment in the NCDF and has been used by more than 2,000 women in England since 2011.

For more details, go to: http://finance.yahoo.com/news/eisai-confirms-life-extending-breast-000100659.html